MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure

Poordad F, Pol S, Asatryan A, et al. MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Buti M, Shaw DR, Hezode C, Lalezari J, Felizarta F, Reindollar R, et al. Gastroenterology. 2017;152(5):S1057.

Publication Type:

Journal Article

Authors:

Poordad, Fred; Pol, Stanislas; Asatryan, Armen; et, al

Source:

Gastroenterology, Volume 152, Issue 5, p.S1057 (2017)

Cited On:

Export Citation:

RIS Format

Top